Interferon‑α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity

Han,Xiao; Shang,Donghao; Han,Tiandong; Xu,Xiuhong; Tian,Ye

doi:10.3892/etm.2014.1691

Interferon‑α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity

Authors:
- Xiao Han
- Donghao Shang
- Tiandong Han
- Xiuhong Xu
- Ye Tian
View Affiliations

Affiliations: Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: April 25, 2014 https://doi.org/10.3892/etm.2014.1691
Pages: 267-273

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the antiproliferative effects of interferon (IFN)‑α and rapamycin (RPM) on renal cell carcinoma (RCC) cells and examine the synergistic growth suppression conferred by IFN‑α and RPM. The effects of IFN‑α and/or RPM on RCC cells were determined using a WST‑1 assay and the synergy of IFN‑α and RPM against three RCC cell lines was analyzed with isobolographic analysis. The expression of mammalian target of rapamycin (mTOR) was downregulated by RNAi, and the expression and phosphorylation of proteins in the mTOR pathway following treatment with IFN‑α and/or RPM was examined by western blot analysis. The observations indicated that IFN‑α significantly increased the susceptibility of RCC cells to RPM and the synergistic effect of IFN‑α and RPM against RCC cells was confirmed in all three RCC cell lines. The mTOR pathway was shown to be associated with the synergistic effect of IFN‑α and RPM against RCC. IFN‑α and RPM alone decreased the phosphorylation of mTOR, p70 S6 kinase, S6 and 4E binding protein 1, and IFN‑α significantly enhanced the RPM‑induced suppression of the mTOR pathway. However, in RCC cells with low mTOR activity, the synergy of IFN‑α and RPM was eliminated. Therefore, the results of the present study indicate that the mTOR pathway plays an important role in the synergistic effect of IFN‑α and RPM against RCC cells. Thus, mTOR may serve as an effective therapeutic target in the treatment of advanced RCC.

View Figures

View References

1	Pantuck AJ, Zisman A and Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol. 166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
2	Hartmann JT and Bokemeyer C: Chemotherapy for renal cell carcinoma. Anticancer Res. 19:1541–1543. 1999.PubMed/NCBI
3	Hernberg M, Pyrhönen S and Muhonen T: Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother. 22:145–154. 1999. View Article : Google Scholar : PubMed/NCBI
4	Yanai Y, Horie S, Yamamoto K, et al: Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro. J Interferon Cytokine Res. 21:1129–1136. 2001. View Article : Google Scholar : PubMed/NCBI
5	Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
6	Rathmell WK and Godley PA: Recent updates in renal rell carcinoma. Curr Opin Oncol. 22:250–256. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kremer CL, Klein RR, Mendelson J, et al: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI
8	Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivières S, Mercep L and Ferrari S: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem. 273:14424–14429. 1998. View Article : Google Scholar : PubMed/NCBI
9	Nozawa H, Watanabe T and Nagawa H: Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett. 251:105–113. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ruvinsky I, Sharon N, Lerer T, et al: Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 19:2199–2211. 2005. View Article : Google Scholar : PubMed/NCBI
11	Seufferlein T and Rozengurt E: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 56:3895–3897. 1996.PubMed/NCBI
12	Grewe M, Gansauge F, Schmid RM, Adler G and Seufferlein T: Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 59:3581–3587. 1999.PubMed/NCBI
13	Cho D, Signoretti S, Regan M, Mier JW and Atkins MB: The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 13:758s–763s. 2007. View Article : Google Scholar : PubMed/NCBI
14	Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M and Suthanthiran M: Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 63:917–926. 2003. View Article : Google Scholar : PubMed/NCBI
15	Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG and Mills GB: Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 55:1982–1988. 1995.PubMed/NCBI
16	Masiello D, Mohi MG, McKnight NC, et al: Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther. 6:195–201. 2007. View Article : Google Scholar : PubMed/NCBI
17	Wu WZ, Sun HC, Shen YF, et al: Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol. 131:169–178. 2005. View Article : Google Scholar : PubMed/NCBI
18	Costa LJ, Gemmill RM and Drabkin HA: Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology. 69:596–602. 2007. View Article : Google Scholar : PubMed/NCBI
19	Linehan WM, Lerman MI and Zbar B: Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA. 273:564–570. 1995. View Article : Google Scholar : PubMed/NCBI
20	Kaelin WG Jr: Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2:673–682. 2002. View Article : Google Scholar : PubMed/NCBI
21	Guba M, von Breitenbuch P, Steinbauer M, et al: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 8:128–135. 2002. View Article : Google Scholar : PubMed/NCBI
22	Treins C, Giorgetti-Peraldi S, Murdaca J, Monthouël-Kartmann MN and Van Obberghen E: Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. Mol Endocrinol. 19:1304–1317. 2005. View Article : Google Scholar : PubMed/NCBI
23	Liu YT, Shang D, Akatsuka S, et al: Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway. Am J Pathol. 171:1978–1988. 2007. View Article : Google Scholar : PubMed/NCBI
24	Berenbaum MC: A method for testing for synergy with any number of agents. J Infect Dis. 137:122–130. 1978. View Article : Google Scholar : PubMed/NCBI
25	Hattori K and Akaza H: New combination chemotherapy in urological cancers. Gan To Kagaku Ryoho. 27:382–387. 2000.(In Japanese).
26	Zhang JF, Liu JJ, Lu MQ, et al: Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transpl Immunol. 17:162–168. 2007. View Article : Google Scholar : PubMed/NCBI
27	Bukowski RM: Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors. Clin Genitourin Cancer. 5:359–361. 2007. View Article : Google Scholar : PubMed/NCBI
28	Amato RJ, Jac J, Mohammad T and Saxena S: Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 6:97–102. 2008. View Article : Google Scholar : PubMed/NCBI
29	Wang Z, Zhou J, Fan J, et al: Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 14:5124–5130. 2008. View Article : Google Scholar : PubMed/NCBI
30	Huynh H, Chow PK, Palanisamy N, et al: Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol. 49:52–60. 2008. View Article : Google Scholar : PubMed/NCBI
31	Shi Y and August DA: A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence. Cancer Biol Ther. 7:397–398. 2008. View Article : Google Scholar : PubMed/NCBI
32	Pectasides D, Pectasides E, Papaxoinis G, et al: Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience. Anticancer Res. 29:769–775. 2009.
33	Vaishampayan UN, Marur S, Heilbrun LK, et al: Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. J Urol. 182:317–323. 2009. View Article : Google Scholar : PubMed/NCBI
34	Hou G, Xue L, Lu Z, Fan T, Tian F and Xue Y: An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 253:236–248. 2007. View Article : Google Scholar : PubMed/NCBI
35	Fan QW and Weiss WA: Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. Methods Mol Biol. 821:349–359. 2012. View Article : Google Scholar : PubMed/NCBI
36	Fingar DC, Salama S, Tsou C, Harlow E and Blenis J: Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16:1472–1487. 2002. View Article : Google Scholar : PubMed/NCBI
37	Rosner M and Hengstschläger M: Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR. Oncogene. 30:4509–4522. 2011. View Article : Google Scholar : PubMed/NCBI
38	Terzis G, Spengos K, Mascher H, Georgiadis G, Manta P and Blomstrand E: The degree of p70 S6k and S6 phosphorylation in human skeletal muscle in response to resistance exercise depends on the training volume. Eur J Appl Physiol. 110:835–843. 2010.PubMed/NCBI
39	Pullen N and Thomas G: The modular phosphorylation and activation of p70s6k. FEBS Lett. 410:78–82. 1997. View Article : Google Scholar : PubMed/NCBI
40	Hinnebusch AG: Translational homeostasis via eIF4E and 4E-BP1. Mol Cell. 46:717–719. 2012. View Article : Google Scholar : PubMed/NCBI
41	Tait S, Dutta K, Cowburn D, Warwicker J, Doig AJ and McCarthy JE: Local control of a disorder-order transition in 4E-BP1 underpins regulation of translation via eIF4E. Proc Natl Acad Sci USA. 107:17627–17632. 2010. View Article : Google Scholar : PubMed/NCBI
42	Pause A, Belsham GJ, Gingras AC, et al: Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature. 371:762–767. 1994.
43	Perier A, Fregni G, Wittnebel S, et al: Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene. 30:2622–2632. 2011. View Article : Google Scholar : PubMed/NCBI